Aimed at avoid future legal spats over diabetes technology-related intellectual property, Medtronic (NYSE:MDT) and Tandem Diabetes Care (NASDAQ:TNDM) had executed a five-year cross-license agreement covering their respective patent portfolios in diabetes. The contract includes a provision not to clone each other’s products.
No payment were exchanged in the matter. Further terms remain confidential.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.